Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Biotech Will Need Cash To Finalize Pivotal Program
Executive Summary
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.